Lumida
/VRTX
⌘K
Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

VRTX
$485.65USD↓-0.08%-0.38 today

MARKET CAP

123.3B

P/E (TTM)

25.8x

FWD P/E

23.8x

DAY RANGE

$482 – $497

52W RANGE

$363
$534

AI Summary

Stalk
StalkMedium

VRTX remains in a Stage 2 advancing regime within a secular uptrend, with medium-term bias bullish supported by higher highs and price above the rising 50-day MA. However, short-term momentum has turned negative, with price rejected at the 9/21 EMA band and overbought conditions evident. Using a SPEC strategy, we will stalk for a pullback into the 21 EMA / 50 DMA support region and require clear acceptance before committing.

  • ↑Q1 2026 revenue rose 8% YoY to $2.99B driven by CF therapy demand
  • ↑Acquisition of Crinetics for $10B adds endocrine pipeline with $5B+ peak potential
  • ↓Shares trade at high valuation, risking correction if growth misses forecasts
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is a leading biotechnology company specializing in developing transformative therapies for serious diseases, particularly cystic fibrosis (CF), sickle cell disease, and renal disorders. Vertex's extensive expertise in drug development is positioned prominently in the fast-evolving landscape of biopharmaceuticals, as they continue to leverage innovative treatments and expand their portfolio into new therapeutic areas, setting a foundation for sustained growth and market leadership.

Bull says

  • ↑Q1 2026 revenue rose 8% YoY to $2.99B driven by CF therapy demand
  • ↑Acquisition of Crinetics for $10B adds endocrine pipeline with $5B+ peak potential
  • ↑FDA approval expanded CASGEVY® use in sickle cell increases addressable market
  • ↑Deployed $344M in Q1 share buybacks; ended quarter with $13B cash
  • ↑Analysts maintain ‘Moderate Buy’ consensus targeting ~$556 per share
  • ↑Strong profitability factors and low volatility bolster quality profile

Bear says

  • ↓Shares trade at high valuation, risking correction if growth misses forecasts
  • ↓Renal pipeline execution hinges on timely FDA approvals for drugs like POVI
  • ↓Rising competition in CF and pain markets may erode market share
  • ↓R&D and SG&A spend climbed 5%, pressuring non-GAAP operating margins
  • ↓Payer coverage challenges for new therapies like Genavix could delay revenue
  • ↓High leverage exposure and weak liquidity factors raise financial risks

Investment themes with VRTX

Quality↑ +0.54%

Companies with strong fundamentals and stability

NVDA · AAPL · MSFT
Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-07-2026neutral

Transcript signals

Bull points

  • overall, by the way, we are extremely pleased with the progress on Genavix. We are fully on track in terms of our prescription numbers and our revenue numbers.
  • the quarter one performance was in line with our expectations. We are absolutely on track to more than triple the number of prescriptions that we delivered in 2025.
  • we have just achieved our 240 million lives covered, as you know. We're very happy with that.

Bear points

  • tolerability issue that we have been monitoring and sharing with you now that the study is being discontinued has to do with lung inflammation, like an inflammatory response, probably in response to the LNP that's being used to deliver it.
  • Anything else you can share on the tolerability issues?
  • We previously disclosed tolerability issues in this program.
Read full transcript analysis ›